[SCHEDULE 13G] Camp4 Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Vivo Opportunity funds disclosed ownership positions in Camp4 Therapeutics (CAMP). Together, Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,561,793 shares, representing 7.6% of the class based on a 46,878,487-share base that includes a 26,717,414-share private placement closed September 11, 2025. Separate Cayman entities, Vivo Opportunity Cayman Fund, L.P. and its GP, report beneficial ownership of 359,775 shares (0.8%). All reported shares are held of record by the named funds, and the filers state sole voting and dispositive power over the shares. The filing is a Schedule 13G indicating passive investment intent.

Positive

• Material disclosure of ownership: Vivo Opportunity reports a 7.6% beneficial stake in Camp4 Therapeutics, providing clarity on a significant shareholder position
• Clear voting and dispositive power disclosed: filers report sole voting and sole dispositive power over the reported shares
• Calculation transparency: Percentage basis is explained using a 46,878,487-share class total that includes a noted private placement of 26,717,414 shares

Negative

• None.

Insights

Financial Analyst

TL;DR: Vivo Opportunity reports a material passive stake of 7.6% in CAMP, increasing share count due to a recent private placement.

The filing discloses a meaningful 7.6% beneficial stake held of record by Vivo Opportunity Fund Holdings, L.P., with sole voting and dispositive power for 3,561,793 shares. The percent is calculated on an expanded share base of 46,878,487 that includes 26,717,414 shares issued in a private placement closed September 11, 2025. As a Schedule 13G, the filer asserts passive intent, which typically signals non-control positioning but still represents a sizable minority holding that could attract investor attention.

Corporate Governance Expert

TL;DR: The disclosure shows clear ownership and voting power; filing certification indicates no intent to influence control.

The report clearly identifies record holders, GPs, and sole voting/dispositive power for each entity: U.S.-organized entities hold 7.6% and Cayman entities hold 0.8%. The signed certification affirms the shares were not acquired to change or influence control, consistent with Schedule 13G treatment. This ownership level requires transparency but does not, by itself, indicate activist governance action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Camp4 Therapeutics Corp

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

13463J101

(CUSIP Number)

09/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 13463J101

1

Names of Reporting Persons

Vivo Opportunity Fund Holdings, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,561,793.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,561,793.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,561,793.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents shares of common stock, $0.0001 par value (the "Common Stock") of Camp4 Therapeutics Corporation (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 46,878,487 shares of Common Stock which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 14, 2025, plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in a private placement transaction closed on September 11, 2025, as reported in the Issuer's current report on Form 8-K, filed with the SEC on September 10, 2025.

SCHEDULE 13G

CUSIP No. 13463J101

1

Names of Reporting Persons

Vivo Opportunity, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,561,793.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,561,793.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,561,793.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 46,878,487 shares of Common Stock which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025, plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in a private placement transaction closed on September 11, 2025, as reported in the Issuer's current report on Form 8-K, filed with the SEC on September 10, 2025.

SCHEDULE 13G

CUSIP No. 13463J101

1

Names of Reporting Persons

Vivo Opportunity Cayman Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 359,775.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 359,775.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

359,775.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage of class is based on 46,878,487 shares of Common Stock which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025, plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in a private placement transaction closed on September 11, 2025, as reported in the Issuer's current report on Form 8-K, filed with the SEC on September 10, 2025.

SCHEDULE 13G

CUSIP No. 13463J101

1

Names of Reporting Persons

Vivo Opportunity Cayman, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 359,775.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 359,775.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

359,775.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage of class is based on 46,878,487 shares of Common Stock which consists of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025, plus (ii) 26,717,414 shares of Common Stock sold by the Issuer in a private placement transaction closed on September 11, 2025, as reported in the Issuer's current report on Form 8-K, filed with the SEC on September 10, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Camp4 Therapeutics Corp
(b)	Address of issuer's principal executive offices: One Kendall Square Building 1400 West, 3rd Floor Cambridge, MA 02139
Item 2.
(a)	Name of person filing: Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC
(b)	Address or principal business office or, if none, residence: 192 Lytton Avenue, Palo Alto, CA 94301
(c)	Citizenship: Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership. Vivo Opportunity, LLC is a Delaware limited liability company. Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership. Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 13463J101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Vivo Opportunity, LLC beneficially owns 3,561,793 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC beneficially owns 359,775 shares of Common Stock. The securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(b)	Percent of class: Vivo Opportunity Fund Holdings, L.P.: 7.6% Vivo Opportunity, LLC: 7.6% Vivo Opportunity Cayman Fund, L.P.: 0.8% Vivo Opportunity Cayman, LLC.: 0.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Vivo Opportunity Fund Holdings, L.P.: 3,561,793 shares Vivo Opportunity, LLC: 3,561,793 shares Vivo Opportunity Cayman Fund, L.P.: 359,775 shares Vivo Opportunity Cayman, LLC: 359,775 shares
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Vivo Opportunity Fund Holdings, L.P.: 3,561,793 shares Vivo Opportunity, LLC: 3,561,793 shares Vivo Opportunity Cayman Fund, L.P.: 359,775 shares Vivo Opportunity Cayman, LLC: 359,775 shares
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Opportunity Fund Holdings, L.P.

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	09/17/2025

Vivo Opportunity, LLC

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	09/17/2025

Vivo Opportunity Cayman Fund, L.P.

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	09/17/2025

Vivo Opportunity Cayman, LLC

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	09/17/2025

FAQ

What stake in Camp4 Therapeutics (CAMP) does Vivo Opportunity report?

Vivo Opportunity Fund Holdings, L.P. and its GP report beneficial ownership of 3,561,793 shares (7.6%); related Cayman entities report 359,775 shares (0.8%).

How was the percent ownership for CAMP calculated in the filing?

The percentage is based on 46,878,487 shares, which includes 20,161,073 shares outstanding as of August 5, 2025, plus 26,717,414 shares sold in a private placement closed September 11, 2025.

Does the Schedule 13G indicate Vivo Opportunity intends to control Camp4 (CAMP)?

No. The filing includes a certification that the securities were not acquired to change or influence control and is submitted as a Schedule 13G (passive intent).

Who has voting and dispositive power over the reported CAMP shares?

The filers state they have sole voting power and sole dispositive power for the reported shares (no shared power reported).

Which entities filed the Schedule 13G for CAMP?

Vivo Opportunity Fund Holdings, L.P.; its general partner Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; and its GP Vivo Opportunity Cayman, LLC filed the disclosure.